Patented Universal Tumor Targeting Drug Delivery
www.GlobalBX.com
Listing ID:
700324483
Listing Title:
Patented Universal Tumor Targeting Drug Delivery
Quick Link:
http://www.globalbx.com/listing.asp?bId=324483
Industry:
Health and Medical
Industry Segment:
Medical Devices
Country:
United States
State / Province:
California
Area
Southern California - All Southern California
City:
Irvine
Asking Price Range:
$10.0M - $20.0M
Gross Revenues:
Seller Will Provide
Cash Flow:
Seller Will Provide
Cash Flow Type:
Sellers Discretionary Cash
Year Established:
2008
Number of Employees:
4 - 5
Business Description:
Patented Universal Tumor-Targeting Drug Delivery Platform Co.
This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer.
The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues.
The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to ''universally'' target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.
The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.
The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug App
« Close this window »